Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have earned an average rating of “Moderate Buy” from the nine research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $6.8571.

PYXS has been the topic of a number of recent research reports. Stifel Nicolaus reduced their price target on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, March 24th. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings lowered shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Wedbush initiated coverage on shares of Pyxis Oncology in a report on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Tuesday, March 24th.

Institutional Trading of Pyxis Oncology

Several hedge funds have recently made changes to their positions in the stock. Maia Wealth LLC acquired a new position in Pyxis Oncology during the 4th quarter valued at approximately $25,000. Engineers Gate Manager LP acquired a new stake in Pyxis Oncology in the fourth quarter worth $26,000. Fox Run Management L.L.C. acquired a new stake in Pyxis Oncology in the fourth quarter worth $26,000. Avanza Fonder AB acquired a new stake in Pyxis Oncology in the fourth quarter worth $31,000. Finally, XTX Topco Ltd bought a new stake in Pyxis Oncology in the second quarter valued at $40,000. Institutional investors own 39.07% of the company’s stock.

Pyxis Oncology Trading Down 4.7%

PYXS stock opened at $2.25 on Tuesday. The firm has a market cap of $142.54 million, a P/E ratio of -1.72 and a beta of 1.30. The stock’s 50 day simple moving average is $2.16 and its 200 day simple moving average is $1.79. Pyxis Oncology has a 12-month low of $0.97 and a 12-month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). On average, research analysts forecast that Pyxis Oncology will post -1.19 EPS for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.